Alembic [APLLTD] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Alembic
NSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Alembic wins in 8 metrics, Divi's Laboratories wins in 12 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alembic | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.11 | 69.93 | Alembic |
| Price-to-Book Ratio | 3.62 | 10.80 | Alembic |
| Debt-to-Equity Ratio | 24.23 | 0.03 | Divi's Laboratories |
| PEG Ratio | 2.11 | 2.64 | Alembic |
| EV/EBITDA | 19.43 | 51.62 | Alembic |
| Profit Margin (TTM) | 8.84% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | 12.13% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | 12.13% | 25.60% | Divi's Laboratories |
| Return on Equity | 11.24% | 14.64% | Divi's Laboratories |
| Return on Assets (TTM) | 7.51% | 12.94% | Divi's Laboratories |
| Free Cash Flow (TTM) | $-4.76B | $2.15B | Divi's Laboratories |
| Dividend Yield | 1.09% | 0.91% | Alembic |
| 1-Year Return | -22.84% | 8.05% | Divi's Laboratories |
| Price-to-Sales Ratio (TTM) | 2.75 | 17.05 | Alembic |
| Enterprise Value | $200.23B | $1,582.14B | Divi's Laboratories |
| EV/Revenue Ratio | 2.94 | 16.39 | Alembic |
| Gross Profit Margin (TTM) | 76.18% | 60.33% | Alembic |
| Revenue per Share (TTM) | $347 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $30.69 | $87.12 | Divi's Laboratories |
| Beta (Stock Volatility) | 0.47 | 0.23 | Divi's Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Alembic vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alembic | 0.18% | -3.70% | -5.74% | -5.14% | -1.44% | -12.12% |
| Divi's Laboratories | -1.45% | -3.52% | -5.63% | -10.47% | 0.96% | -2.90% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alembic | -22.84% | 52.47% | -0.52% | 31.45% | 1,882.58% | 1,882.58% |
| Divi's Laboratories | 8.05% | 59.15% | 92.40% | 423.74% | 1,578.48% | 7,650.03% |
News Based Sentiment: Alembic vs Divi's Laboratories
Alembic
News based Sentiment: MIXED
September brought both positive regulatory developments – USFDA approvals for API facilities and a new injectable product – and conflicting reports regarding Q1 earnings. While shareholder support and insider buying are encouraging, the mixed financial performance and analyst ratings create a complex investment picture, making this a moderately significant month for Alembic.
Divi's Laboratories
News based Sentiment: MIXED
September brought both challenges and opportunities for Divi's Laboratories. While sequential declines in financial results and a downgrade raised concerns, positive analyst coverage from JPMorgan and StockInvest.us, coupled with expansion into high-growth areas, offered a more optimistic outlook. This creates a mixed investment narrative.
Performance & Financial Health Analysis: Alembic vs Divi's Laboratories
| Metric | APLLTD | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹186.95B | ₹1.63T |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 124,855 | 416,899 |
| 90 Day Avg. Volume | 89,622 | 389,167 |
| Last Close | ₹921.90 | ₹5,897.00 |
| 52 Week Range | ₹725.20 - ₹1,303.90 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -29.30% | -16.61% |
| All-Time High | ₹1,303.90 (Oct 07, 2024) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -29.30% | -16.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.14% |
| Quarterly Earnings Growth | 0.15% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.24% |
| Operating Margin (TTM) | 0.12% | 0.26% |
| Return on Equity (TTM) | 0.11% | 0.15% |
| Debt to Equity (MRQ) | 24.23 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹264.09 | ₹563.87 |
| Cash per Share (MRQ) | ₹4.25 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹-3,101,700,000 | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹5.83B | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.09% | 0.91% |
| Last 12-Month Dividend | ₹11.00 | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Alembic vs Divi's Laboratories
| Metric | APLLTD | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.11 | 69.93 |
| Forward P/E | 21.95 | 108.21 |
| PEG Ratio | 2.11 | 2.64 |
| Price to Sales (TTM) | 2.75 | 17.05 |
| Price to Book (MRQ) | 3.62 | 10.80 |
| Market Capitalization | ||
| Market Capitalization | ₹186.95B | ₹1.63T |
| Enterprise Value | ₹200.23B | ₹1.58T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.94 | 16.39 |
| Enterprise to EBITDA | 19.43 | 51.62 |
| Risk & Other Metrics | ||
| Beta | 0.47 | 0.23 |
| Book Value per Share (MRQ) | ₹264.09 | ₹563.87 |
Financial Statements Comparison: Alembic vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | APLLTD | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹17.11B | ₹24.10B |
| Cost of Goods Sold | ₹4.07B | ₹9.56B |
| Gross Profit | ₹13.03B | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.08B | ₹6.17B |
| EBITDA | ₹2.87B | ₹8.48B |
| Pre-Tax Income | ₹1.90B | ₹7.33B |
| Income Tax | ₹364.80M | ₹1.88B |
| Net Income (Profit) | ₹1.54B | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | APLLTD | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹834.80M | ₹4.15B |
| Total Current Assets | ₹40.88B | ₹100.81B |
| Total Current Liabilities | ₹24.12B | ₹14.52B |
| Long-Term Debt | ₹467.70M | ₹20.00M |
| Total Shareholders Equity | ₹51.90B | ₹149.69B |
| Retained Earnings | ₹43.94B | ₹134.00B |
| Property, Plant & Equipment | ₹4.45B | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | APLLTD | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | APLLTD | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 124,855 | 416,899 |
| Average Daily Volume (90 Day) | 89,622 | 389,167 |
| Shares Outstanding | 196.56M | 265.47M |
| Float Shares | 57.33M | 120.77M |
| % Held by Insiders | 0.71% | 0.52% |
| % Held by Institutions | 0.16% | 0.29% |
Dividend Analysis & Yield Comparison: Alembic vs Divi's Laboratories
| Metric | APLLTD | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | ₹11.00 | ₹60.00 |
| Last 12-Month Dividend Yield | 1.09% | 0.91% |
| 3-Year Avg Annual Dividend | ₹13.33 | ₹50.00 |
| 3-Year Avg Dividend Yield | 1.17% | 0.70% |
| 3-Year Total Dividends | ₹40.00 | ₹150.00 |
| Ex-Dividend Date | Jul 29, 2025 | Jul 25, 2025 |